Agustín Ciapponi, Ariel Bardach, Agustina Mazzoni, Tomás Alconada, Steven Anderson, Fernando J Argento, Jamile Ballivian, Karin Bok, Daniel Comandé, Emily Erbelding, Erin Goucher, Beate Kampmann, Ruth Karron, Flor M Munoz, María Carolina Palermo, Edward P K Parker, Federico Rodriguez Cairoli, María Victoria Santa, Andy Stergachis, Gerald Voss, Xu Xiong, Natalia Zamora, Sabra Zaraa, Mabel Berrueta, Pierre M Buekens
Background: Pregnant women with COVID-19 are at an increased risk of severe COVID-19 illness as well as adverse pregnancy and birth outcomes. Many countries are vaccinating or considering vaccinating pregnant women with limited available data about the safety of this strategy. Early identification of safety concerns of COVID-19 vaccines, including their components, or their technological platforms is therefore urgently needed. Methods: We conducted a rapid systematic review, as the first phase of an ongoing full systematic review, to evaluate the safety of COVID-19 vaccines in pregnant women, including their components, and their technological platforms (whole virus, protein, viral vector or nucleic acid) used in other vaccines, following the Cochrane methods and the PRISMA statement for reporting (PROSPERO-CRD42021234185)...
June 6, 2021: medRxiv